Biomarkers of bone disease in persons with haemophilia

被引:10
|
作者
Goldscheitter, Galen [1 ]
Recht, Michael [2 ]
Sochacki, Paul [3 ]
Manco-Johnson, Marilyn [4 ]
Taylor, Jason A. [1 ,2 ]
机构
[1] Portland VA Med Ctr, Portland, OR 97239 USA
[2] Oregon Hlth & Sci Univ, Hemophilia Ctr, 3181 Sw Sam Jackson Pk Rd, Portland, OR 97239 USA
[3] Bio Lab Analyt LLC, Vancouver, WA USA
[4] Univ Colorado, Hemophilia & Thrombosis Ctr, Anschutz Med Campus, Aurora, CO USA
关键词
biomarkers; bone diseases; cytokines; hemophilia A; humans; MINERAL DENSITY; OSTEOCLAST DIFFERENTIATION; BIOCHEMICAL MARKERS; CHILDREN; RESORPTION; METABOLISM; TURNOVER; LIGAND; MICE;
D O I
10.1111/hae.13986
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction Persons with haemophilia (PwH) have abnormally low bone density and increased risk of fractures. We previously demonstrated decreased skeletal health in factor VIII (FVIII)-deficient mice. Thus, we hypothesized factor deficiency is an independent risk factor for decreased skeletal health. Aim We seek to identify differences in bone-related cytokine expression among PwH and healthy controls. Methods We evaluated plasma samples from 79 participants with severe FVIII deficiency and 51 age-matched healthy controls. Plasma samples were assessed for RANKL and OPG, cytokines that regulate bone metabolism, and CTX-1, a biomarker for bone resorption, as well as 10 bone-related cytokines. Results CTX-1 is higher among samples from FVIII-deficient participants compared to controls (P < .01) but not among participants with recent factor use (within 24 hours of sample collection) (P = .21). Among PwH greater than 16 years of age (PwH >= 16), OPG is increased with recent factor use (P < .01) but not without (P = .34). Lower levels of TNF-alpha (P < .01), interleukin (IL)-12 (P < .01) and IL-10 (P < .001) were found among samples from PwH. Controlling for subject age, IL-12 and IL-10 levels are lower in PwH >= 16 (P < .01,P < .001) but not PwH under 16 (PwH < 16) (P > .05). Levels of TNF-alpha were lower among PwH < 16 only (P < .05). These differences are not observed in participants with recent factor use. Conclusions In PwH, markers of bone metabolism and circulating cytokine levels are abnormal. Recent factor use reverses many of these differences suggesting FVIII replacement ameliorates this pathology. This study suggests bone disease present in PwH is intrinsic to FVIII deficiency.
引用
收藏
页码:149 / 155
页数:7
相关论文
共 50 条
  • [1] Bone health in persons with haemophilia
    Kempton, C. L.
    Antoniucci, D. M.
    Rodriguez-Merchan, E. C.
    [J]. HAEMOPHILIA, 2015, 21 (05) : 568 - 577
  • [2] Bone health in persons with haemophilia: a review
    Ghosh, Kanjaksha
    Shetty, Shrimati
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2012, 89 (02) : 95 - 102
  • [3] Bone health in haemophilia carriers and persons with von Willebrand disease: A large database analysis
    Citla-Sridhar, Divyaswathi
    Sidonio, Robert F., Jr.
    Ahuja, Sanjay P.
    [J]. HAEMOPHILIA, 2022, 28 (04) : 671 - 678
  • [4] Management of cardiovascular disease in aging persons with haemophilia
    Schutgens, Roger E. G.
    Voskuil, Michiel
    Mauser-Bunschoten, Evelien P.
    [J]. HAMOSTASEOLOGIE, 2017, 37 (03): : 196 - +
  • [5] Guidance for the antithrombotic management of persons with haemophilia and cardiovascular disease
    Mannucci, Pier Mannuccio
    Agosti, Pasquale
    Lettino, Maddalena
    [J]. HAEMOPHILIA, 2023, 29 (06) : 1390 - 1393
  • [6] Biomarkers of cartilage and bone damage as a measure of joint damage in haemophilia
    Jansen, Nathalic W. D.
    Roosendaal, Goris
    Lundin, Bjorn
    Heijnen, Lily
    Bijlsma, Johannes W. J.
    Lafeber, Floris P. J. G.
    [J]. ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S655 - S656
  • [7] Multifactorial aetiology for bone disease in patients with haemophilia
    Ghosh, Kanjaksha
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2013, 90 (05) : 435 - 435
  • [8] Pharmacokinetics and biomarkers in persons with haemophilia a (PwHA) receiving emicizumab every 2 or 4 weeks
    Kiialainen, A.
    Schmitt, C.
    Adamkewicz, J. I.
    Petry, C.
    Pipe, S.
    Young, G.
    Mahlangu, J.
    Lehle, M.
    Chang, T.
    Dhalluin, C.
    Jimenez-Yuste, V.
    Meeks, S.
    Oldenburg, J.
    Shima, M.
    Chebon, S.
    Niggli, M.
    Negrier, C.
    Levy, G. G.
    [J]. HAEMOPHILIA, 2019, 25 : 45 - 46
  • [9] Biomarkers of Cartilage and Bone Damage as a Measure of Joint Damage in Haemophilia.
    Jansen, Nathalie W. D.
    Roosendaal, Goris
    Lundin, Bjorn
    Heijnen, Lily
    Theobald, Matthias
    Bijlsma, Johannes W. J.
    Lafeber, Floris P. J. G.
    [J]. BLOOD, 2008, 112 (11) : 442 - 442
  • [10] Bone disease in patients with haemophilia. What is true?
    Anagnostis, Panagiotis
    Garipidou, Vasilia
    Kazantzidou, Eirini
    Vakalopoulou, Sofia
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2013, 90 (05) : 434 - 434